Hi Snuuze,
Here is an abstract about Nplate (Romiplostim) in MDS patients.
"The proportion of pts experiencing a significant bleeding event decreased from 23% during weeks 1–12 to 0% during weeks 48–60. Similarly, the proportion of pts receiving a platelet transfusion decreased from 28% during weeks 1–12 to 0% during weeks 48–60. 85% had a platelet response. The median duration of platelet response was 41 weeks (15–87 weeks)."
"Peripheral blasts were increased in 2 pts (MDS-U and RA at baseline) and resolved in both cases after discontinuation of romiplostim. Three cases of progression to AML were reported, corresponding to an annual on-study event rate of 5.9%."
http://cancercaresouthtexas.com/docu..._Safety_an.pdf
I am still waiting for results from studies about Promacta in MDS patients - we can hope that Promacta won't increase blast cells but we know that both drugs can increase bone marrow fibrosis. Still MDS patients in this forum report good results from both drugs.
Kind regards
Birgitta-A